Supplements
Supplements

Vitamin D Receptor Pathways in Uterine Fibroids

By Marcus Reid ·

How Vitamin D Signalling Controls Fibroid Growth

Researchers have completed a scoping review linking vitamin D and its receptor to uterine leiomyomas. The study examines clinical, molecular, and genetic evidence. Uterine leiomyomas remain the most common benign tumours of the female reproductive tract. They are a leading cause of gynaecological morbidity worldwide. The review synthesises observational and experimental findings on how vitamin D signalling influences fibroid growth.

The review highlights that vitamin D acts through the vitamin D receptor (VDR) to regulate cell proliferation and apoptosis. In uterine tissue, VDR expression varies significantly between fibroid and normal myometrium. Genetic polymorphisms in the VDR gene may alter receptor function. These variations could explain why some women develop fibroids while others do not. The evidence suggests that low vitamin D status removes a natural brake on smooth muscle cell division.

Vitamin D binds to the VDR, which then regulates genes involved in cell cycle control. When vitamin D levels drop, this regulatory pathway weakens. Fibroid cells can then proliferate unchecked. The review notes that experimental models show vitamin D supplementation reduces fibroid volume in animal studies. Clinical trials in humans have shown mixed but generally positive results. Some studies report symptom improvement and reduced fibroid size after supplementation.

Why Do Some Women Develop Fibroids?

The genetic component is critical. Specific VDR polymorphisms are associated with increased fibroid risk. The review identifies several single nucleotide polymorphisms that alter receptor binding affinity. Women carrying certain VDR variants may have impaired vitamin D signalling. This impairment removes protective effects on uterine smooth muscle. The interplay between genetics and vitamin D status determines individual susceptibility.

The findings point toward personalised prevention strategies. Women with low vitamin D and specific VDR genotypes may benefit most from supplementation. Future research should focus on biomarker-guided therapy. Clinicians can use vitamin D levels and VDR genotyping to identify high-risk patients. This approach could reduce fibroid burden and improve quality of life for affected women.

Frequently Asked Questions

Does vitamin D supplementation shrink existing fibroids? Some clinical trials show modest reductions in fibroid volume. The effect is more pronounced in women with initially low vitamin D levels. Results vary by study design and patient population.

Are VDR gene variants common in the general population? Yes, VDR polymorphisms are prevalent. Specific variants are linked to fibroid susceptibility. Genetic testing can identify at-risk individuals.

Can vitamin D prevent fibroid development? Evidence suggests adequate vitamin D status may lower risk. The review supports maintaining sufficient levels as a preventive measure. More large-scale studies are needed to confirm this.